Mitomycin 40 mg powder for solution for injection — generic (India) Mitomycin Targeted cancer therapy. Delivery from Europe within 4-5 days, storage conditions observed, payment upon receipt. Order by calling +380996042415, Viber, WhatsApp.

Composition

active ingredient:mitomycin;

excipients: sodium chloride.

Dosage Form

Powder for injection solution.

Pharmacological group

Antineoplastic antibiotics. ATC code L01D C03.

readings

Reduction of subjective and objective symptoms associated with the following diseases: chronic lymphocytic leukemia, chronic myelogenous leukemia, stomach cancer, colorectal cancer, lung cancer, pancreatic cancer, liver cancer, cervical cancer, endometrial cancer, breast cancer, head and neck cancer, and bladder cancer.

Contraindications

Hypersensitivity to mitomycin.Thrombocytopenia, blood clotting disorders, and increased bleeding. Pregnancy and breastfeeding.

Method of use and dosage

Used by adults in specialized medical institutions. The dose and duration of treatment are determined individually, depending on the severity of the disease, the patient's condition, and the age of the patient.

Intermittent use.

Usually 4-6 mg of mitomycin C Kiovo is prescribed intravenously 1-2 times a week.

Sequential use.

Usually 2 mg of mitomycin C Kiovo is prescribed intravenously once a day.

Intermittent use of a high dose.

Mitomycin is usually prescribed intravenously at 10-30 mg 1-3 (or more) times a week.

Concomitant use with other antineoplastic agents.

Mitomycin is usually used at a dose of 2-4 mg 1-2 times a week in combination with other antineoplastic agents.

Preparation of injection solution.

The drug is dissolved directly in the vial in a ratio of 5 ml of distilled water for injection to 2 mg of mitomycin C Kiovo. Administered as a slow injection.

Bladder cancer.

Typically, to prevent relapses, 4-10 mg of mitomycin is prescribed in the bladder daily or every 2 days.For therapeutic purposes, 10-40 mg of mitomycin C is administered into the urinary bladder once a day. The dose may be adjusted according to the patient's age and severity of symptoms.

If necessary, Mitomycin can also be administered intra-arterially, intramedullary, intrapleural, and intraperitoneally at a dosage of 2-10 mg daily. The dose may be divided depending on the patient's age and the severity of symptoms.

Adverse Reactions

Hematological complications: leukopenia, thrombocytopenia, hemorrhage, anemia (rarely - microangiopathic hemolytic anemia).

Liver:rarely - liver dysfunction. Kidneys:hemolytic uremic syndrome or proteinuria, hematuria, edema. Gastrointestinal tract:anorexia, nausea and vomiting, stomatitis.

Allergic reactions:rash.

Urinary system:cystitis, hematuria, or bladder atrophy caused by bladder instillation therapy. Respiratory system:Interstitial pneumonia and pulmonary fibrosis.

Others:rarely - symptoms of malaise, alopecia.

Overdose

Possible increased side effects. Treatment is symptomatic.

Use during pregnancy and breastfeeding

The drug is contraindicated during pregnancy, as there are reports of a possible embryotoxic effect of mitomycin.

Breastfeeding should be discontinued during treatment.

Children

The drug is not prescribed for children.

Special safety measures

The drug is used under constant medical supervision by patients:

• with impaired liver function;
• with impaired kidney function;
• with suppressed bone marrow hematopoiesis;
• with disorders caused by infectious diseases
• with chickenpox (life-threatening complications may occur).

Application Features

The drug is used in specialized medical institutions. Administration should be carried out with caution to prevent extravasation of the drug causing tissue sclerosis or necrosis.

To avoid angialgia, phlebitis, and thrombosis, the drug should be administered as slowly as possible, paying careful attention to the choice of injection site and method.

Mitomycin is incompatible with low pH during solution preparation.